WO2005095389A1 - 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 - Google Patents
複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 Download PDFInfo
- Publication number
- WO2005095389A1 WO2005095389A1 PCT/JP2005/006111 JP2005006111W WO2005095389A1 WO 2005095389 A1 WO2005095389 A1 WO 2005095389A1 JP 2005006111 W JP2005006111 W JP 2005006111W WO 2005095389 A1 WO2005095389 A1 WO 2005095389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- difluoromethyl
- dimethylmorpholino
- active ingredient
- morpholinopyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention has the general formula (I)
- X is a nitrogen atom or CH
- Y is C-C alkyl
- R is a morpholino group (1-4 C
- -R alkyl may be substituted with a hydrogen atom or C -C alkyl
- antineoplastic agent comprising the heterocyclic compound as an active ingredient.
- HMM Hexamethylmelamine
- TEM is known as an alkylating agent, and is an s-triazine derivative having an antitumor effect based on a cell killing effect.
- HMM has already been marketed in Europe as a drug with indications for ovarian cancer and small cell lung cancer, and its effects on solid tumors have attracted attention.
- s-triazine derivatives there are imidazolyl-s-triazine derivatives having both a cell killing action and a selective aromatase inhibitory action. It has been proposed as a therapeutic agent for benign breast disease, endometrial cancer, breast cancer, etc. (for example, see Patent Document 1).
- Non-Patent Document 1 B. Shi Johnson et al. Cancer, 42: 2157-2161 (1978)
- Patent Document 1 WO 93/17009 pamphlet
- Patent Document 2 WO 99/05138 pamphlet
- Patent Document 3 WO 00/43385 pamphlet
- Patent Document 4 WO 02/088112 pamphlet
- Non-Patent Document 1 there is still room for improvement in the strength of HMM against tumor tumors against solid tumors.
- the imidazolyl-s-triazine derivative disclosed in Patent Document 1 has an aromatase inhibitory effect which is considerably stronger than a cell killing effect. Since it may lead to the occurrence of side effects such as menstrual abnormalities and its application range is limited, the development of a drug that does not have aromatase inhibitory activity and is effective against solid tumors has been desired.
- the present inventors have found that a heterocyclic compound of the general formula (I) having a 16-xy group has remarkable improvements in blood kinetics and an excellent effect on antitumor activity, thereby completing the present invention.
- the heterocyclic compound of the present invention is a compound represented by the general formula (I).
- the meanings and examples of the terms used in the definition of each symbol in the formula are described below.
- C 1 -C means a group having 1 to 6 carbon atoms without limitation.
- C-C alkyl includes methyl, ethyl, n-propyl, iso-propyl, n-butyl,
- Examples thereof include linear or branched alkyl groups such as tert-butyl, n-pentyl, and n-hexyl.
- Examples of the compound of the present invention include the following compounds, but the present invention is not limited to these compounds.
- a compound in which a methoxy group is substituted at the 4-position of the benzimidazole ring of the general formula (I) is particularly preferable.
- the compound of the present invention has an asymmetric carbon atom in its structure, there are isomers derived from asymmetric carbon atoms and mixtures thereof, all of which are compounds of the present invention. Included in things.
- the compound of the present invention represented by the general formula (I) is prepared by reacting cyanide chloride as shown in the following reaction formula. Or 2,4,6-trichloro-open pyrimidine (I-Danied Compound II) as a starting material, and benzimidazole-i-Danied Compound (I-Danied Compound V), morpholine-i-Danied Compound (I-Danied Compound VI) and H (Ii)
- the compound (VII) can be produced by sequentially reacting.
- Examples of the hydrogen chloride scavenger used in this reaction include sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, triethylamine, pyridine and the like.
- As the solvent, acetone, tonolene examples include xane, xylene, dioxane, tetrahydrofuran or dichloroethane, and ⁇ , ⁇ -dimethylformamide (DMF).
- compound V can also be used as a hydrogen salt scavenger.
- the intermediate m obtained in the above step (0) is reacted with a morpholine-conjugated compound (a compound VI) to obtain an intermediate IV.
- a salt-trapping hydrogen scavenger used in this reaction the same ones as in the above-mentioned production step (the salt-riding hydrogen scavenger of 0) can be mentioned, and as the solvent, DMF, acetone, toluene, xylene, dichloroethane, dichloromethane And the like.
- the compound VI can also be used as a hydrogen salt scavenger.
- the compound (I) of the present invention can be obtained by reacting the intermediate IV obtained in the production step (ii) with R H (compound VII) in a solvent in the presence of a hydrogen chloride scavenger.
- Examples of the hydrogen chloride scavenger used in this reaction include the same hydrogen chloride scavenger as used in the production step (0).
- Solvents such as DMF, dimethyl sulfoxide (DMSO), xylene, and dichloromethane Compound VII can also be used as a solvent.
- compound (I) when compound VI and compound VII are the same in the production of compound (I), compound (I) can be obtained by performing production step (iO, (m) in one step.
- the reaction is carried out at -10 ° C to 5 ° C for 0.1 to 5 hours using 2 to 10 moles of the compound VI or VII with respect to the compound mimol, and further at room temperature to 120 ° C for 3 to 50 hours.
- the production process follows the reaction conditions of GO.
- the product obtained in each of the above steps can be separated and purified as necessary by a usual method, for example, extraction, concentration, neutralization, filtration, recrystallization, column chromatography, or the like.
- test compound numbers in Tests 1 and 2 correspond to the compound numbers in Examples described later.
- HPLC used a reversed-phase column, and the eluent used was an acetonitrile-phosphate buffer (pH 2.5) system.
- Test compound AUC (.ug-h / ml)
- Test compound AUC ( ⁇ g'h / m ⁇
- the compounds of the present invention having a methoxy group ⁇ ethoxy group at the 4-position of the benzimidazole ring are known compounds A, B, and C having a hydroxyl group at the 4-position of the benzimidazole ring.
- D and D it was found to show clearly superior blood kinetics.
- the significant increase in AUC is due to the fact that the compounds of the present invention show the highest blood concentration (lh-24h) compared to the comparative compound.
- the relative tumor growth rate was calculated by dividing the tumor volume on each measurement day by the tumor volume on the sample administration start day, and was calculated from the relative tumor growth rate (T) of the sample administration group and the relative tumor growth rate (C) of the control group T / C (%) was calculated.
- T relative tumor growth rate
- C relative tumor growth rate
- Test compound GI M Test compound GI M) Compound 1 0.45 Compound A 0.15
- the compound of the present invention was also effective in in vitro tests using human colon cancer cells, human lung cancer cells, human breast cancer cells ⁇ human prostate cancer cells, and the like, and thus can be applied to various human solid cancer treatments. Be expected.
- the compound of the present invention can be administered orally or parenterally, and the dosage form for oral administration includes tablets, coated tablets, powders, granules, capsules, microcapsules, syrups and the like.
- the dosage form for oral administration injection preparations (including freeze-dried preparations for injection to be dissolved and used at the time of use), suppositories and the like can be used.
- the preparation of these dosage forms may include pharmaceutically acceptable excipients, binders, lubricants, disintegrants, suspending agents, emulsifiers, preservatives, stabilizers and dispersants, such as lactose, sucrose, It is performed using starch, dextrin, crystalline cellulose, kaolin, calcium carbonate, talc, magnesium stearate, distilled water or physiological saline.
- pharmaceutically acceptable excipients such as lactose, sucrose, It is performed using starch, dextrin, crystalline cellulose, kaolin, calcium carbonate, talc, magnesium stearate, distilled water or physiological saline.
- the dose varies depending on the patient's condition, age, body weight, and the like, but the daily dose to an adult can be 50 to 500 mg once or in divided doses.
- the compound of the present invention can remarkably improve pharmacokinetics, has a markedly stronger antitumor effect than conventional s-triazine derivatives and pyrimidine derivatives without aromatase inhibitory effect, and is applied to the treatment of solid cancer. it can.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05727794A EP1741714B1 (en) | 2004-03-31 | 2005-03-30 | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient |
AU2005227954A AU2005227954B2 (en) | 2004-03-31 | 2005-03-30 | Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component |
DK05727794.9T DK1741714T3 (da) | 2004-03-31 | 2005-03-30 | Heterocyklisk forbindelse og middel mod ondartet turmor, der indeholder denne som aktiv ingrediens |
KR1020067022675A KR101130913B1 (ko) | 2004-03-31 | 2005-03-30 | 헤테로시클릭 화합물 및 이를 활성 성분으로서 포함하는항악성종양제 |
US10/594,994 US7855199B2 (en) | 2004-03-31 | 2005-03-30 | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient |
ES05727794T ES2400056T3 (es) | 2004-03-31 | 2005-03-30 | Compuesto heterocíclico y agente anti tumores malignos que comprende el mismo como componente eficaz |
CA2561406A CA2561406C (en) | 2004-03-31 | 2005-03-30 | Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component |
JP2006511743A JP4733021B2 (ja) | 2004-03-31 | 2005-03-30 | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 |
HK07110520.1A HK1105202A1 (en) | 2004-03-31 | 2007-09-27 | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004103273 | 2004-03-31 | ||
JP2004-103273 | 2004-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005095389A1 true WO2005095389A1 (ja) | 2005-10-13 |
Family
ID=35063701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006111 WO2005095389A1 (ja) | 2004-03-31 | 2005-03-30 | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7855199B2 (ja) |
EP (1) | EP1741714B1 (ja) |
JP (1) | JP4733021B2 (ja) |
KR (1) | KR101130913B1 (ja) |
CN (1) | CN100532380C (ja) |
AU (1) | AU2005227954B2 (ja) |
CA (1) | CA2561406C (ja) |
DK (1) | DK1741714T3 (ja) |
ES (1) | ES2400056T3 (ja) |
HK (1) | HK1105202A1 (ja) |
WO (1) | WO2005095389A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095906A1 (ja) * | 2005-03-11 | 2006-09-14 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 |
US7307077B2 (en) | 2001-04-27 | 2007-12-11 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as effective ingredient |
WO2008032077A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
WO2009066775A1 (ja) | 2007-11-22 | 2009-05-28 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
WO2011005119A1 (en) | 2009-07-07 | 2011-01-13 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
WO2012020762A1 (ja) * | 2010-08-10 | 2012-02-16 | アステラス製薬株式会社 | へテロ環化合物 |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US9056852B2 (en) | 2011-03-28 | 2015-06-16 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
CN105175410A (zh) * | 2015-10-14 | 2015-12-23 | 湖南华腾制药有限公司 | 三嗪类化合物及其制备方法和抗肿瘤应用 |
US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009120094A2 (en) * | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
EP2397479A4 (en) | 2009-02-12 | 2012-08-01 | Astellas Pharma Inc | HETERO RING DERIVATIVE |
WO2012044641A1 (en) * | 2010-09-29 | 2012-04-05 | Pathway Therapeutics Inc. | 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010024A1 (en) * | 1994-09-26 | 1996-04-04 | Daiichi Pharmaceutical Co., Ltd. | Pyrimidinylpyrazole derivative |
WO2002088112A1 (fr) * | 2001-04-27 | 2002-11-07 | Zenyaku Kogyo Kabushiki Kaisha | Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif |
WO2004032930A1 (ja) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | 癌の処置方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100563514B1 (ko) * | 1997-07-24 | 2006-03-27 | 젠야쿠코교가부시키가이샤 | 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제 |
ES2389253T3 (es) * | 2002-10-25 | 2012-10-24 | Zenyaku Kogyo Kabushiki Kaisha | Compuestos heterocíclicos y agentes antitumorales que comprenden los mismos como ingrediente activo |
-
2005
- 2005-03-30 CA CA2561406A patent/CA2561406C/en not_active Expired - Fee Related
- 2005-03-30 WO PCT/JP2005/006111 patent/WO2005095389A1/ja active Application Filing
- 2005-03-30 US US10/594,994 patent/US7855199B2/en not_active Expired - Fee Related
- 2005-03-30 AU AU2005227954A patent/AU2005227954B2/en not_active Ceased
- 2005-03-30 EP EP05727794A patent/EP1741714B1/en not_active Not-in-force
- 2005-03-30 JP JP2006511743A patent/JP4733021B2/ja not_active Expired - Fee Related
- 2005-03-30 ES ES05727794T patent/ES2400056T3/es active Active
- 2005-03-30 CN CNB2005800102150A patent/CN100532380C/zh not_active Expired - Fee Related
- 2005-03-30 KR KR1020067022675A patent/KR101130913B1/ko active IP Right Grant
- 2005-03-30 DK DK05727794.9T patent/DK1741714T3/da active
-
2007
- 2007-09-27 HK HK07110520.1A patent/HK1105202A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010024A1 (en) * | 1994-09-26 | 1996-04-04 | Daiichi Pharmaceutical Co., Ltd. | Pyrimidinylpyrazole derivative |
WO2002088112A1 (fr) * | 2001-04-27 | 2002-11-07 | Zenyaku Kogyo Kabushiki Kaisha | Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif |
WO2004032930A1 (ja) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | 癌の処置方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1741714A4 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7307077B2 (en) | 2001-04-27 | 2007-12-11 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as effective ingredient |
US7750001B2 (en) | 2005-03-11 | 2010-07-06 | Zenyaku Kogyo Kabushikikaisha | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
WO2006095906A1 (ja) * | 2005-03-11 | 2006-09-14 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 |
US8338414B2 (en) | 2005-03-11 | 2012-12-25 | Zenyaku Kogyo Kabushikikaisha | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
WO2008032077A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
AU2008327095B2 (en) * | 2007-11-22 | 2013-07-25 | Ohara Pharmaceutical Co., Ltd. | Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
WO2009066775A1 (ja) | 2007-11-22 | 2009-05-28 | Zenyaku Kogyo Kabushikikaisha | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
JP5479912B2 (ja) * | 2007-11-22 | 2014-04-23 | 全薬工業株式会社 | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
JPWO2009066775A1 (ja) * | 2007-11-22 | 2011-04-07 | 全薬工業株式会社 | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
EP2409975A1 (en) | 2007-11-22 | 2012-01-25 | Zenyaku Kogyo Kabushikikaisha | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
US8227463B2 (en) | 2007-11-22 | 2012-07-24 | Zenyaku Kogyo Kabushiki Kaisha | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
US9108980B2 (en) | 2009-03-27 | 2015-08-18 | Vetdc, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8772287B2 (en) | 2009-03-27 | 2014-07-08 | Vetdc, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
WO2011005119A1 (en) | 2009-07-07 | 2011-01-13 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
JPWO2012020762A1 (ja) * | 2010-08-10 | 2013-10-28 | アステラス製薬株式会社 | へテロ環化合物 |
US8912180B2 (en) | 2010-08-10 | 2014-12-16 | Astellas Pharma Inc. | Heterocyclic compound |
WO2012020762A1 (ja) * | 2010-08-10 | 2012-02-16 | アステラス製薬株式会社 | へテロ環化合物 |
JP5765342B2 (ja) * | 2010-08-10 | 2015-08-19 | アステラス製薬株式会社 | へテロ環化合物 |
EA023931B1 (ru) * | 2010-08-10 | 2016-07-29 | Астеллас Фарма Инк. | Гетероциклическое соединение |
US9056852B2 (en) | 2011-03-28 | 2015-06-16 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10064868B2 (en) | 2011-03-28 | 2018-09-04 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10335415B2 (en) | 2011-03-28 | 2019-07-02 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US10603324B2 (en) | 2011-03-28 | 2020-03-31 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US11400097B2 (en) | 2011-03-28 | 2022-08-02 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
CN105175410A (zh) * | 2015-10-14 | 2015-12-23 | 湖南华腾制药有限公司 | 三嗪类化合物及其制备方法和抗肿瘤应用 |
US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
Also Published As
Publication number | Publication date |
---|---|
CA2561406A1 (en) | 2005-10-13 |
CA2561406C (en) | 2012-07-03 |
AU2005227954B2 (en) | 2011-02-10 |
HK1105202A1 (en) | 2008-02-06 |
KR101130913B1 (ko) | 2012-03-28 |
EP1741714A4 (en) | 2007-09-12 |
CN1972935A (zh) | 2007-05-30 |
US20080287431A1 (en) | 2008-11-20 |
US7855199B2 (en) | 2010-12-21 |
EP1741714B1 (en) | 2013-01-09 |
JP4733021B2 (ja) | 2011-07-27 |
EP1741714A1 (en) | 2007-01-10 |
KR20070008670A (ko) | 2007-01-17 |
DK1741714T3 (da) | 2013-04-15 |
AU2005227954A1 (en) | 2005-10-13 |
ES2400056T3 (es) | 2013-04-05 |
JPWO2005095389A1 (ja) | 2008-02-21 |
CN100532380C (zh) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005095389A1 (ja) | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 | |
US7071189B2 (en) | Heterocyclic compound and antitumor agent containing the same as active ingredient | |
US7153853B2 (en) | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | |
KR100563514B1 (ko) | 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제 | |
JP5089377B2 (ja) | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 | |
CN107698603B (zh) | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 | |
CN111233774A (zh) | 一种胺基嘧啶类化合物 | |
US20230406804A1 (en) | Protein kinase inhibitors | |
CN116529249A (zh) | 吡啶并嘧啶酮类化合物 | |
US20230399332A1 (en) | IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF | |
WO1997029749A1 (fr) | Agent therapeutique contre les maladies renales | |
JP2004075563A (ja) | 放射線増感剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005227954 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2561406 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006511743 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580010215.0 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005227954 Country of ref document: AU Date of ref document: 20050330 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005227954 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727794 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067022675 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727794 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10594994 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067022675 Country of ref document: KR |